CVS Health CorpCVSBUY ON WEAKNESSApr 14, 2015Stock price when the opinion was issued
As of Jun 05, 2026. Market Open.
Bought at less than 10x earnings with recent dividend increase is good for share price appreciation. Recent M&A also good for investors. Will continue to own shares. Excellent management team and solid dividend. Weakness is sector creating opportunities to buyout competitors.
Price target was raised today. This peaked in 2020-1 then was hit with a lot of bad news, like doubts over Signify and Oak Street acquisitions. But that negative sentiment has reversed, like their Medicare Advantage stars rating has gone up, and the street sees profitability rising in their pharmacy benefits management system, based on a new model last month. Trades under a cheap PE and pays a 3% dividend. He targets over $100 in 12 months. Is underloved and over-owned.
Healthcare has lagged this year. They run a chain of pharmacies, Aetna health insurance, pharmacy management and recently bought Oak Health. The CEO is doing a great job, and shares are not expensive around 8.5x PE. They took one some debt to bought some companies, but once they integrated them, it will ramp up cash flow.
(Analysts’ price target is $87.45)
A drug retailer in the US as well as having a PBM (Pharmacy Benefits Manager), where they go to employers and help them structure their benefit plans. The stock has done very well. She likes drug retail. PBM is very competitive and is all about lower costs, so you need scale. Fully valued here and she would want at least a 10% pullback. In this area, she would prefer the Canadian name, such as Loblaw’s (L-T).This one is on her watch list.